A Multicenter Phase I/II Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of RY_SW01cell Injection Therapy in Active Lupus Nephritis
Latest Information Update: 24 Jan 2024
At a glance
- Drugs RY SW01 (Primary)
- Indications Lupus nephritis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Renocell Biotech Company
Most Recent Events
- 06 Oct 2023 New trial record